Good Lifestyle

There has been significant progress in weight loss drugs in recent years, revolutionizing the treatment of patients who have trouble losing weight. Injectable GLP-1 drugs like Ozempic and Wegovy have taken a large part of the spotlight, despite some of their potential side effects, their availability problems and their high costs. But it may not take long before a new option is available for anyone in a weight loss journey, thanks to a revolutionary obesity pill which, according to scientists, works in a completely different way.

In relation: Doctors warn that drugs like Ozempic make you "lean fat".

Researchers say that the Sana molecule can burn fat cells.

In a press release of June 23, the Institut Pasteur de Montevideo and the University of the Republic (Udelar) announced that the Uruguayan pharmaceutical company Eolo Pharma had been successful in a phase I test of its recently developed test Sana molecule .

The experience, which was Posted last month in the newspaper Metabolism of nature , enlisted 44 human participants who were either healthy weight, lean weight, or clinically obese. The results showed that those who took a high dose of the compound (which was 200 mg per day) lost 3% of their body weight in just 15 days without any significant muscle loss compared to a placebo group.

The same high -dose group has also experienced improvements in resistance to glucose and insulin - everything without any changes in appetite or serious side effects, even among the highest group of 800 mg per day.

In relation: Ozempic and Wegovy may have landed 25,000 people in the emergency room - here is the frightening reason .

What is the difference between GLP-1 and Sana drugs?

There is a clear difference between Sana and GLP-1 agonists Like Ozempic, Wegovy and Mounjaro.

Existing drugs, some of which are intended for the management of type 2 diabetes and prescribed out of AMM for weight loss - imitating a natural hormone that regulates appetite, digestion and blood sugar, according to the Cleveland Clinic.

By slowing down the emptying of the stomach and reducing the amount of glucose released in the bloodstream, injectable drugs can help patients to eat less, possibly resulting in weight loss.

On the other hand, Sana works by marking metabolism at the cellular level. Essentially, it burns fat cells to burn calories while resting in the same way as during physical exercise. This helps in particular to preserve lean muscle mass without affecting appetite and improving blood sugar control.

Recently published research has been built on the results of a previous study played on mice. In this document, the researchers discovered that the compound stimulated burning energy in white fat cells as opposed to brown fat cells which generally metabolize during the exercise, reports new atlas.

Essentially, Sana increases metabolism fueled by creatine by reconfiguring a protein called L-Arginine: Glycine Amindinotransferase (Agat), which also allows a single dose to have a lasting effect. Researchers conducting the latest study indicate that this could have important implications for future treatments.

"This result opens up a whole new therapeutic path for obesity and metabolic disorders - the one that completes GLP -1 therapies but focuses on improving the body's energy combustion capacity rather than simply suppressing appetite", " Carlos Escande , PHD, a researcher at IP Montevideo and member of Eolo Pharma, said about the results of the human study of phase I in the press release.

In relation: A new weight loss drug has patients who lose fats without losing muscle .

Other human tests are expected soon.

Despite the positive results, there are still potential risks of use of Sana. This includes the responses of the involuntary immune system that could see modified proteins as invaders, according to a new atlas.

However, the researchers say they hope to start a higher clinical clinical human trial before the end of the year which will include more participants, including those with type 2 diabetes.

"What is exciting in this study is the transition of preclinical analysis to the clinical application of the real world", the Metabolism of nature The editorial team wrote in a research briefing accompanying the study. They added that the revolutionary result "justifies other clinical trials to assess its use as a treatment of obesity".

In relation: Is the little-known supplement called "Ozempic de la Nature"-Does it really work for weight loss?

The point to take away:

A recent study conducted on humans has shown promising results for a new compound of weight loss known as Sana. The molecule works by launching white fat cells in burning calories even at rest by modifying a specific protein.

The results of the published study have shown that a group taking a high dose of 200 mg per day saw a 3% reduction in body fat without losing lean muscle mass in the process. And unlike the GLP-1 agonist drugs like Wegovy and Ozempic, that does not affect appetite, and there have been no negative side effects reported in the group, taking the most important dose of 800 mg per day.

Other clinical studies are expected to start later this year.

"This work was a constant challenge, and it is incredibly rewarding to see that the results of human tests follow the same trend that we have observed in our laboratory models", " Karina Cal , the main author of the study and researcher at IP Montevideo, said in a press release.